Zimmerman BioPharmaceuticals to Propel 665 Energy
November 01 2019 - 7:00AM
InvestorsHub NewsWire
Zimmerman BioPharmaceuticals to Propel 665
Energy
OKLAHOMA CITY, OK -- November
1, 2019 -- InvestorsHub NewsWire -- 665 Energy,
Inc. (OTC:
SSOF) has acquired Zimmerman
BioPharmaceuticals, PBC (ZBP), the
owner of a
proprietary
process that will
deliver insulin to consumers at 80%
of current prices. The global
market for
human insulin was $42.9 billion in
2017*. Within the next two years,
the global demand for insulin will increase by
47%.*
The ZPB process lowers
production costs, improves product cycle
time, and delivers greater product
stability.
Zimmerman BioPharmaceuticals
has invested more than 7 years and $6 million
in
developing
their
proprietary process. Zimmerman's
biosimilar
insulin has been fully validated in pre-clinical trials and
testing.
The company has received an FDA recommendation to seek
approval through the accelerated 505(b)(2) NDA
process.
Dr. Ron Zimmerman is the
Founder and Chief Science Officer of Zimmerman
BioPharmaceuticals, PBC. Dr. Zimmerman served as the
Chief Scientist at Eli Lilly for more than 30 years. His career in
the biopharma industry also includes 20 years of building
and
selling
biopharmaceutical businesses, where he developed and patented
processes that greatly improve insulin
manufacturing. Dr. Zimmerman served as the co-founder
and
President of IPT,
Inc., which sold to IVAX
Corporation at a 500% internal rate of return (IRR). IVAX later
sold to Teva Pharmaceutical Industries for $7.4 billion (Nasdaq:
TEVA)
Mr. David Wood leads Zimmerman
BioPharmaceuticals as President and CEO
with
35+ years
experience as an operations executive in start-ups
and
Fortune 25
companies; delivering rapid revenue
growth, and building teams to sustain
growth & profitability. He was the CRO for Scient Inc., VP
& GM for the $180 million Enterprise BU, and
the President & COO for The Joseph Company valued at $40
million. He served as a
Captain
in
the United States
Army, and holds a Bachelor of Science,
Magna Cum Laude, from Northeastern University.
Mr. Jim
Frazier, the previous CEO of 665
Energy Inc., has tendered his resignation
and controlling interest of the company effective
immediately.
* www.psmarketresearch.com
& International Diabetes Federation Global Atlas
2015
ABOUT
Zimmerman BioPharmaceuticals,
INC.
Zimmerman
BioPharmaceuticals, Inc, is a biopharmaceutical company
that owns a proprietary
process that will
deliver biosimilar
alternatives to
biologic medicines at a lower cost to
consumers. Its process lowers production costs,
improves product cycle time, and delivers greater product
stability. Zimmerman's
products
have been fully validated
in pre-clinical
trials and testing, and has an FDA recommendation to seek
approval through an accelerated
process.
For more information,
contact:
Zimmerman
BioPharmaceuticals, Inc.
info@zbpinc.com
www. zbpinc.com
SAFE HARBOR
AND INFORMATIONAL STATEMENT
This press release
may contain forward-looking information within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended (the
Exchange Act), including all statements that are not statements of
among other things: (i) the Company's financing plans; (ii) trends
affecting the Company's financial condition or results of
operations; (iii) the Company's growth strategy and operating
strategy; and (iv) the declaration and payment of dividends. The
words "may", "would", "will", "expect", "estimate", "anticipate",
"believe", "intend" and similar expressions and variations thereof
are intended to identify forward-looking statements. Investors are
cautioned that any such forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties, many of which are beyond the Company's ability to
control, and that actual results may differ materially from those
projected in the forward-looking statements as a result of various
factors including the risk disclosed in the Company's reports filed
with the SEC. The Company is not eligible to rely on the safe
harbor provided by Section 21E(c) of the Exchange Act because it is
not subject to filing periodic reports under Sections 13 or 15(d)
of the Exchange Act.
Sixty Six Oilfield Servi... (CE) (USOTC:SSOF)
Historical Stock Chart
From Oct 2024 to Nov 2024
Sixty Six Oilfield Servi... (CE) (USOTC:SSOF)
Historical Stock Chart
From Nov 2023 to Nov 2024